Trial Profile
Phase II open-label dose optimization clinical trial of Zalypsis (PM00104) in patients with relapsed/refractory multiple myeloma [Ensayo clínico de fase II, de optimización de dosis, abierto, de Zalypsis (PM00104) en pacientes con mieloma múltiple recaído/refractario]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 May 2022
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; PM 00104 (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- Sponsors PharmaMar
- 12 Apr 2022 Status changed from recruiting to completed, according to European Clinical Trials Database.
- 21 Jun 2011 New trial record